In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Arrowhead Pharmaceuticals trades far above its fair value of $33.52, indicating significant overvaluation with a -43.1% implied downside. Financial health is poor, with zero profitability and efficiency scores, despite strong liquidity. Valuation methods diverge widely, but Monte Carlo analysis shows no downside risk below the current price.